Ncoa2 Promotes CD8+ T cell-Mediated Antitumor Immunity by Stimulating T-cell Activation via Upregulation of PGC-1α...

Area of Science:

• Immunology
• Molecular Biology
• Cell Biology

Background:

• Nuclear receptor coactivator 2 (Ncoa2) is known to regulate regulatory T cell differentiation.
• The role of Ncoa2 in CD8+ T-cell function remained unexplored.

Purpose of the Study:

• To investigate the function of Ncoa2 in CD8+ T-cell-mediated anti-tumor immune responses.
• To elucidate the molecular mechanisms by which Ncoa2 influences CD8+ T-cell activity.

Main Methods:

• Utilized Ncoa2-deficient mouse models (Ncoa2fl/fl/CD4Cre) to assess anti-tumor immunity.
• Analyzed CD8+ T-cell activation, mitochondrial function, and PGC-1α expression upon T-cell receptor stimulation.
• Investigated the molecular interaction between Ncoa2, CREB, and PGC-1α enhancers.

Main Results:

• Ncoa2 deficiency in T cells resulted in defective anti-tumor immunity against MC38 tumors, with reduced CD8+ T cells and IFNγ production.
• Ncoa2-deficient CD8+ T cells exhibited impaired mitochondrial function, including reduced oxidative phosphorylation and lower PGC-1α expression.
• T-cell activation-induced CREB phosphorylation recruited Ncoa2 to PGC-1α enhancers, promoting its expression.

Conclusions:

• Ncoa2 is crucial for CD8+ T-cell-mediated anti-tumor immunity by enhancing mitochondrial function via PGC-1α upregulation.
• Restoring PGC-1α expression in Ncoa2-deficient CD8+ T cells rescued mitochondrial function, T-cell activation, and anti-tumor responses.
• Ncoa2 represents a potential therapeutic target for modulating CD8+ T-cell anti-tumor immune responses.